Demeetra provides solutions to the biggest challenges facing our clients when adopting CRISPR & transposase technology for commercial cell line development. By combining our own Cas-CLOVER IP with the CVC, key holders of foundational CRISPR IP, we have cleared the path for our clients to obtain straightforward commercial licenses with undeniable FTO. Our transposase, Harbor-IN, outperforms other transposases and requires no licenses or fees. Through innovative licensing strategies and products, combined with the efficient transfer of validated, in-house expertise, we make advanced gene editing accessible and practical for any company looking to leverage these technologies commercially.